Synthetic double-stranded oligonucleotides for specific inhibition of gene expression

US8772469B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Eugen Uhlmann · Königstein, DE
• Jochen Huber · Mittelbiberach, DE
• Niki Gunkel · Heidelberg, DE
• Sandra Neumann · Offenbach, DE

Key dates

• Filing date: Jul 11, 2002
• Grant date: Jul 8, 2014
• Expiry date: Jul 11, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/51
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to oligonucleotide derivatives which are at least partly double-stranded and which have a 2′5′-linked oligonucleotide residue on at least one 3′ end and to the use thereof for specific inhibition of gene expression.